[Effects of advanced glycation end-products on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes].
OBJECTIVE
To investigate the effects of advanced glycation end-products (AGEs) on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes (CMs) cultured in vitro.


METHODS
CMs already cultured for 3 to 5 d in vitro were continuously cultured with DMEM supplemented with 1% or 10% fetal bovine serum for 24 h, prior to exposure to AGE-modified human serum albumin (AGE-HSA, at 50 and 100 microg/ml) for 12, 24 and 48 h. Cells cultured in the same manner but without AGE-HSA treatment served as the control group. All cells were collected and analyzed by flow cytometry for cell cycle distribution and cell apoptosis, and the number of apoptotic body/nucleus of CMs was determined by in situ cell death detection kit (fluorescein).


RESULTS
AGEs had no obvious effects on cell cycle distribution in CMs, but could increase the number of apoptotic body/nucleus of CMs in a time-dependent manner to up to 0.55 and 1.23 times at 24 and 48 h respectively, as compared with the number at 12 h in control cells. AGEs at 50 and 100 microg/ml increased the number of apoptotic body/nucleus of CMs to various degrees at different time points: 0.74 and 1.21 times respectively at 12 h; 1.15 and 1.78 times at 24 h; 0.83 and 1.19 times at 48 h. The average number of apoptotic body/nucleus of the cells treated with 100 microg/ml AGEs at 12, 24, 48 h were 0.27, 0.29, 0.20 times respectively that of the cells with 50 microg/ml AGEs treatment.


CONCLUSIONS
AGEs do not affect the distribution of cell cycle but can impair neonatal rat CMs by increasing their apoptosis rate.
Zeng
Ping
P
Department of Cardiology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. zengping@fimmu.com
Xu
Ding-li
DL
Li
Zhen
Z
Lai
Wen-yan
WY
Ren
Hao
H
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D017127:Glycation End Products, Advanced / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000494:pharmacology*; D000075462:Serum Albumin, Human
D017127:Glycation End Products, Advanced; D012709:Serum Albumin; C109748:advanced glycation end products-human serum albumin; D000075462:Serum Albumin, Human